IMM 4.11% 38.0¢ immutep limited

prr anounce success

  1. 3,176 Posts.
    Prima Biomed Limited (ASX: PRR) today announced that preliminary
    experiments have been completed in a small number of sheep which have
    all demonstrated strong immune responses following immunisation with
    a DCtag vaccine.

    The DCtag vaccine platform technology was first announced in November
    2001 after very promising immune responses had been demonstrated in
    animal tests. In a one-dose vaccination against malaria, mice were
    successfully protected against a lethal malaria infection and high
    antibody levels had continued to persist for 4 months.

    In addition to promoting strong antibody responses, DCtag has
    demonstrated strong killer cell type immune responses in mice. DCtag
    pre-immunisation prevented tumour growth and immunisation eradicated
    pre-existing tumours.

    DCtag vaccines are unique as they promote a response by two immune
    cell types - antibody and killer T-cell type immune responses.

    Mr Marcus Clark, Chief Executive Officer of Prima Biomed said "The
    outcome of this latest sheep trial is very encouraging and as a
    result we will immediately commence further studies to give us a more
    detailed picture of the immune response.

    "The new study will determine the relative potency and spectrum of
    activity of the immune response using a DCtag vaccine. These further
    experiments will take up to 6 months and are designed to demonstrate
    that DCtag can induce the same levels of antibody and killer T cells
    in sheep as was demonstrated in mice.

    "If successful Prima would then explore whether the antibodies and
    killer T cells produced by DCtag provide protection against a known
    infection in sheep, cattle or pigs. Such a study would involve first
    vaccinating animals with a DCtag vaccine, exposing them to the
    infectious organism of interest and then monitoring them to see if
    they remain infection free. The company is currently evaluating
    potential infectious disease models for this study.

    "This progress is in line with milestones established in the Panvax
    Business Plan.

    "Such studies, in large animals, form part of the process of
    collecting the necessary data for early human clinical trials. The
    generation of this data also provides the company with potential
    licensing opportunities with large veterinary supply companies. This
    development has the potential to an early revenue stream," said Mr


    Marcus Clark Chief Executive Officer 03 9287 0637
    Rudi Michelson (Monsoon Communications) 03 9620 3199

watchlist Created with Sketch. Add IMM (ASX) to my watchlist
(20min delay)
Mkt cap ! $329.1M
Open High Low Value Volume
35.5¢ 38.0¢ 35.5¢ $534.6K 1.444M

Buyers (Bids)

No. Vol. Price($)
1 100000 37.5¢

Sellers (Offers)

Price($) Vol. No.
38.5¢ 19260 1
View Market Depth
Last trade - 16.10pm 17/05/2022 (20 minute delay) ?
0.015 ( 4.28 %)
Open High Low Volume
35.5¢ 37.5¢ 35.5¢ 226540
Last updated 15.59pm 17/05/2022 (live) ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.